More on the immune privilege of glioblastoma

Neuro-Oncology

Volumn 14, Issue 5, 2012, Pages 527-528

  Weller, Michael ^a  

^a EANO ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CHEMOKINE; CHEMOKINE RECEPTOR CCR4; MACROPHAGE DERIVED CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA;

CANCER IMMUNOTHERAPY; EDITORIAL; GENE CONTROL; GLIOBLASTOMA; HUMAN; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

BRAIN NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; GLIOBLASTOMA; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASM PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 84860355930     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos110     Document Type: Editorial

References (3)

1. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-b, T cell apoptosis, and the immune privilege of the brain. Brain Res Rev 1995;21:128-151.
2. Jacobs JF, Idema AJ, Bol KF, Grotenhuis JA, de Vries IJ, Wesseling P, Adema GJ. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol 2010;225:195-199.
3. Crane CA, Ahn BJ, Seunggu J, Han SJ, Parsa AT. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival and expansion of regulatory T cells: implications for immunotherapy. Neuro-Oncology 2012;14:584-595.